73534-56-2

Usage

Uses

Used in Pharmaceutical and Medicinal Applications:
(R)-3-methyl-3,4-dihydroquinoxalin-2(1H)-one is utilized as a building block in the synthesis of other organic compounds, particularly those with potential pharmaceutical and medicinal uses. Its specific enantiomeric properties allow for the development of targeted therapeutic agents, contributing to the advancement of novel treatments in the healthcare industry.
Used in Materials Science:
In the field of materials science, (R)-3-methyl-3,4-dihydroquinoxalin-2(1H)-one has potential applications in the creation of organic semiconductor materials. Its unique structure and properties make it a valuable compound for research and development in this area, potentially leading to innovations in electronic and optoelectronic devices.
Used in Chemical Synthesis:
(R)-3-methyl-3,4-dihydroquinoxalin-2(1H)-one serves as a precursor in the development of various organic compounds, showcasing its versatility in chemical synthesis. Its role in creating new molecules for different applications across various industries highlights the compound's importance in the field of chemistry.

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 167823-32-7 1,2:5,6-di-O-isopropylidene-α-D-glucofuranos-3-O-yl α-bromopropionate 
• 1192307-88-2 (2-methoxy-2-oxo-(S)-1-phenylethyl) α-bromopropanoate 
• 73938-47-3 ethyl (2S)-<2-bromo-1-oxopropyloxy>propanoate 
• 617-35-6 2-oxo-propionic acid ethyl ester 
• 1417715-06-0 O,O'-di(α-bromopropanoyl)-L-tartaric acid diisopropyl ester 
• 1493-27-2 ortho-nitrofluorobenzene 

Relevant academic research and scientific papers

Metal-free tandem cyclization/hydrosilylation to construct tetrahydroquinoxalines

A one-pot tandem procedure involving cyclization and sequential hydrosilylation of imines and amides under the catalysis of B(C6F5)3 has been developed for the step-economical construction of 1,2,3,4-tetrahydroquinoxalines directly from readily available 1,2-diaminobenzenes, α-ketoesters and low-cost, safe polymethylhydrosiloxane (PMHS). This metal-free approach provides various products in good to excellent yields, and displays a wide range of substrate scope and a high degree of functional group tolerance even to reduction-sensitive moieties. The choice of hydrosilanes is critical to the catalysis, and PMHS has proved to be optimal. Decreasing the amount of PMHS could enable the reaction to stop at the 3,4-dihydroquinoxalin-2(1H)-one stage. The procedure is convenient and scalable, and neither a dried solvent nor an inert atmosphere is required. Moreover, the enantioselective construction of these products was explored, and promising results were achieved.

Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β

Traditional fragment-based drug discovery (FBDD) relies heavily on structural analysis of the hits bound to their targets. Herein, we present a complementary approach based on diversity-oriented synthesis (DOS). A DOS-based fragment collection was able to produce initial hit compounds against the target GSK3β, allow the systematic synthesis of related fragment analogues to explore fragment-level structure-activity relationship, and finally lead to the synthesis of a more potent compound.

(S)-Mandelate-mediated dynamic kinetic resolution of α-bromo esters for asymmetric syntheses of aminoflavones, dihydroquinoxalinones and dihydrobenzoxazinones

(S)-Mandelate-mediated dynamic kinetic resolution of α-bromo esters in nucleophilic substitution reaction has been investigated. Reactions of various aryl amine nucleophiles in the presence of TBAI and DIEA can provide the substitution products 2 and 7-19

Diacetone-D-glucose-mediated asymmetric syntheses of dihydroquinoxalinones

Asymmetric syntheses of dihydroquinoxalinones by diacetone-D-glucose mediated nucleophilic substitution of α-bromo esters have been investigated. Stereoselective reactions with various 1,2-phenylenediamine nucleophiles in the presence of TBAI and DIEA and

Stereochemistry of fully acetylated tetrahydropterins and tetrahydroquinoxalines

Completely acetylated derivatives of naturally occurring tetrahydro-D-monapterin, (6R)-2-acetamido-6-[(1R,2R)-1,2,3-triacetoxypropyl]-5,8-diacetyl-5,6,7,8-tetrahydropteridin-4(3H)-one, show plus and minus CD signs at λ 280 and 240 nm, respectively. Simila